Time and place
- 25. Oct 2022, 2:30 PM - 3:30 PM
Title: From bench to chairside: Stem cells in bone augmentation
Abstract: The value of and potential of stem cell-based therapies were explored in the early 1990s when therapeutically relevant tissue-supportive cells, such as mesenchymal stem cells (MSC), were applied for the regeneration of skeletal tissues. This new approach using cell therapy for bone regeneration is promising and could be used as an alternative for the classic gold standard treatment with bone grafts.
11 patients took part in the first project, and more than 100 patients are taking part in the ongoing EU project where they are treated to compare the safety and efficacy of autologous, cultured stem cells - combined with bi-calcium phosphate biomaterials (BCP) with autologous bone grafting in alveolar bone augmentation prior to dental implants.
Osteonecrosis is a therapy-resistant condition that causes significant discomfort for a large number of patients globally, and that currently has limited therapeutic options. The number of patients taking bone-modulating drugs is increasing, which emphasizes the need for developing reliable treatment options for this growing group of patients.
In OsteoStem project, led by Kamal Mustafa and Evelyn Neppelberg, the researchers are evaluating the safety and efficacy of stem cells in the treatment of bone defects in patient with necrosis.
About the speaker: Kamal Mustafa is a professor and leader of the Tissue Engineering Research Group and Center of Translational Oral Research (TOR), Department of Clinical Dentistry (IKO) at University of Bergen.
More about his work here: Tissue Engineering Group – Engineering for life
One of the four core projects of MRCRM is led by professor Mustafa. More about the project: Using stem cells for clinical treatment of osteonecrosis - Helse Bergen (helse-bergen.no)